METASTATIC HER2+ DISEASE: HOW TODAY'S TOOLS HELP US IMPROVE THE FUTURE OF OUR PATIENTS

Breast cancer represents the most frequent malignancy in the female sex and the leading cause of cancer-related death in women. Recent years have been marked by major advances in the treatment of metastatic disease that have led to a significant improvement in survival, thanks to a strategy increasingly focused on personalization.
In particular, scientific advances in HER2+ disease have improved outcomes for these patients but increased survival remains a primary goal for metastatic stage patients.
The goal of this project is, in addition to scientific updates on the possibilities offered by new treatment options, to identify what issues need to be addressed within the care pathway of metastatic HER2+ patients in order to understand how to optimize their management by sharing experiences from diverse and international clinical settings.
Indeed, the management of HER2+ metastatic patients requires an integrated approach that takes into account the complexity of the disease and involves a variety of professionals and tools, such as RWE (real world evidence and SDM (shared decision making), to ensure the best possible outcome in terms of survival and well-being.

22 maggio 2024 
WEBINAR diretta zoom

ore 14.00  Introduction and course objectives – M.V.Dieci, C.De Angelis
ore 14.05  Discussion of survey results – A.Botticelli, C.Criscitiello, C.DeAngelis, M.V.Dieci
SESSION I: TODAY
ore 14.15  Therapeutic highlights in the treatment of patients with Her2+ metastatic breast cancer:
                  The evolution of therapeutic sequences – C.Criscitiello
ore 14.35  The importance of real world data and patient reported outcome - M.Di Maio
ore 14.55  Lecture: Optimal management of patients with brain metastases – G.Griguolo
ore 15.15  Round table:
                  Clinical scenarios and optimal therapeutic strategies in patients with mBC
                  G.Griguolo, I.Meattini, F.DiMeco
                  Moderano C.Criscitiello, A.Botticelli
SESSION II: TOMORROW
ore 15.55  Lecture: the future of treatments: new drugs and combinations, leading ADCs? – F.Andrè
ore 16.15  The Digital Pathology and AI: the future of breast cancer pathology - N.Fusco
ore 16.30  Possible applications of AI in breast cancer radiology – D.La Torre
ore 16.45  Round table: Sharing decision making and the dialogue with patients (oncologists, patient representative, pathologist)
                  R.D'Antona, G.Arpino, A.Toss, N.Fusco / Moderano: M.V.Dieci, C.DeAngelis
ore 17.15  Sum up and closing – A.Botticelli, C.Criscitiello
ore 17.30  Termine webinar

Il test di valutazione ed il modulo di qualità percepita saranno disponibili al termine dell'ultimo webinar e dovranno essere compilati entro le 24.00 del 25/05/2024

Per la fruizione e l'accesso al corso FAD saranno necessari un computer (Windows o Mac) dotato di connettività internet, di un browser di navigazione standard (Internet Explorer, Firefox, Chrome, Opera, Safari) e di un programma per l'apertura e la lettura dei file PDF (per esempio: Adobe Acrobat Reader).
Per la fruizione della diretta sarà necessario installare il programma gratuito ZOOM, Potete effettuare il download del programma, e le relative istruzioni di installazione su https://zoom.us/download

Questionario (obbligatoriamente a risposta multipla) da compilare entro le ore 24.00 del 25/05/2024

Attenzione: la nuova normativa ministeriale in vigore dal 01/07/2019 prevede che:

• soglia di superamento: 75% delle risposte corrette
• numero massimo tentativi: 5

L’assegnazione dei crediti formativi è subordinata alla partecipazione effettiva del programma e al superamento della verifica di apprendimento.